NCT05059301已完成3 期
A Phase 3, Randomized, Double-blind, Multi-country Study to Evaluate Consistency, Safety, and Reactogenicity of 3 Lots of RSVPreF3 OA Investigational Vaccine Administrated as a Single Dose in Adults Aged 60 Years and Above
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 770
- 试验地点
- 20
- 主要终点
- RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)
研究概览
简要总结
The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults ≥ 60 years of age (YOA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Study is double blind from start to final analysis after which the study is considered single blind.
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol. A male or female ≥ 60 YOA at the time of first study intervention administration.
- •Participants living in the general community or in an assisted living facility that provides minimal assistance, such that the participant is primarily responsible for self care and activities of daily living.
- •Written or witnessed informed consent obtained from the participant prior to performance of any study specific procedure.
- •Participants who are medically stable in the opinion of the investigator at the time of vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, can participate in this study if considered by the investigator as medically stable.
排除标准
- •Medical conditions
- •Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history, and physical examination (no laboratory testing required).
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
- •Hypersensitivity to latex.
- •Serious or unstable chronic illness.
- •Any history of dementia or any medical condition that moderately or severely impairs cognition.
- •Recurrent or un controlled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
- •Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
- •Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
- •Prior/Concomitant therapy
- •Use of any investigational or non registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before study intervention administration and ending 30 days after study intervention administration, or planned use during the study period.
- •Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the study intervention administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after the study vaccination.
- •Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. Previous vaccination with an RSV vaccine.
- •Administration of long acting immune modifying drugs or planned administration at any time during the study period.
- •Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the administration of the study intervention or planned administration during the study period.
- •Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune modifying drugs during the period starting 90 days prior to the study intervention administration or planned administration during the study period. For corticosteroids, this will mean prednisone ≥ 20 mg/day or equivalent. Inhaled and topical steroids are allowed.
- •Prior/Concurrent clinical study experience
- •Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non investigational vaccine/product (drug or invasive medical device).
- •Other exclusions
- •History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
- •Planned move during the study period that will prohibit participating in the study until study end.
- •Bedridden participants.
- •Participation of any study personnel or their immediate dependents, family, or household members.
结局指标
主要结局
RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)
时间窗: At 30 days post-vaccination (Day 31)
Enzyme-linked immunosorbent assay (ELISA) was used to assess the concentrations of IgG antibodies against RSV PreF3 in serum samples.
次要结局
- Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)(From Day 1 up to study end (6 months after vaccination))
- Percentage of Participants Reporting at Least One Unsolicited Adverse Event(Within 30 days (the day of vaccination and 29 subsequent days) after study intervention administration)
- RSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI)(At 30 days post-vaccination (Day 31))
- Percentage of Participants Reporting Solicited Administration Site Events(Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration)
- Percentage of Participants Reporting Solicited Systemic Events(Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration)
- Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)(From Day 1 up to study end (6 months after vaccination))
研究者
研究点 (20)
Loading locations...
相似试验
招募中
3 期
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeChickenpoxNCT06740630GlaxoSmithKline1,840
已完成
2 期
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult PopulationInfluenzaNCT00377585GlaxoSmithKline3,350
进行中（未招募）
3 期
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedDiphtheriaWhooping CoughTetanusNCT05091619China National Biotec Group Company Limited2,898
已完成
3 期
Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio VaccinePoliomyelitisNCT04386707Sinovac Biotech Co., Ltd1,300
进行中（未招募）
3 期
Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23Healthy VolunteersNCT06314867Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd990